Androgenic alopecia affects up to 50% of men and 40% of women over their lifetimes — yet the clinical options available to practitioners have changed little in decades. Exosome-based scalp therapy represents a meaningful shift in how we approach this condition at the follicular level. For aesthetic clinicians, hair loss is no longer a condition to refer elsewhere. As patients seek non-invasive, science-backed solutions beyond finasteride and minoxidil, the demand for in-clin

When clinics compare exosome skin boosters, the conversation usually starts and ends with growth factor counts or stem cell origin claims. One of the most clinically meaningful — and most overlooked — specifications is something far more measurable: particle size. It's also one of the reasons P198 ExoHealer™ is formulated the way it is. A growth factor figure printed on a spec sheet tells you almost nothing on its own. What matters is whether the particles carrying those grow

Platelet-rich plasma has been a mainstay of regenerative esthetics for over two decades. Australian and New Zealand clinics have adopted it widely — for skin rejuvenation, hair restoration, and a growing range of dermatological applications. The evidence base is solid, the safety profile is well established, and the autologous nature of the treatment aligns with patient demand for biologics over synthetics. But PRP has a well-documented ceiling. Growth factors degrade rapidly

Thread lifting has established itself as one of the most clinically documented minimally invasive procedures in facial rejuvenation. For practitioners across Australia and New Zealand, understanding the mechanism, evidence base, and practical application of PDO threads is the foundation for confident patient selection, informed counselling, and reproducible outcomes. MINT stands for Minimally Invasive Nonsurgical Thread. This guide draws on published clinical data from studie

Thread lifting has matured from a fringe technique into a central pillar of minimally invasive facial rejuvenation. Global adoption has accelerated sharply, driven by patient demand for natural-looking outcomes without surgical downtime — and by a new generation of aesthetic physicians who understand that structural support and biostimulation are not mutually exclusive goals. Yet with growth comes proliferation. The PDO thread market now hosts an expanding field of manufactur

Part 2 of 3 — Bridging the Exosome Gap · For Clinicians & Practitioners Missed Part 1? Read: Why Autologous Exosomes Outperform Non-Autologous Exosomes The exosome therapy market is expanding rapidly, and with it comes an equally rapid proliferation of commercial products — many of which make claims that outpace the evidence. As a clinician, you are already fielding questions from patients who have encountered exosome products marketed across aesthetics, regenerative medicine

Part 2 of The Power of Injectable Autologous Exosomes This is Part 2 of our series on the Power of Injectable Autologous Exosomes. If you missed Part 1, read it here first: Because of these measurement challenges, the concentration numbers provided on commercially sold exosome vials should be understood in context. Many commercial vials also contain additional bioactive ingredients such as hyaluronic acid, vitamins, peptides, and growth factors — and in some of these products

Introduction Building on the foundation of The Power of Injectable Autologous Exosomes: Introducing the MCT Metacell Technology System, it becomes clear that the true differentiator in exosome-based therapy is not merely the presence of exosomes—but the origin, integrity, and method of delivery. The MCT framework is specifically engineered around one core principle: that clinically effective regenerative signaling must be both biologically compatible and precisely delivered.